Skip to content

Clinical Evaluation of the Nucleus 5 Cochlear Implant (CI) System

Clinical Evaluation of the Nucleus 5 Cochlear Implant System

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01072409
Enrollment
49
Registered
2010-02-22
Start date
2010-03-31
Completion date
2012-11-30
Last updated
2016-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hearing Loss

Keywords

Speech perception ability in the CI alone condition

Brief summary

To evaluate the performance of the Nucleus 5 Cochlear Implant System.

Detailed description

Performance outcomes of newly implanted adult recipients using the Nucleus 5 Cochlear Implant System.

Interventions

DEVICENucleus 5 Cochlear implant

Cochlear implant surgery

DEVICECochlear implantation

Implantation

Sponsors

Cochlear
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Eighteen years of age or older at the time of the study. * Postlinguistic onset of bilateral severe-to-profound sensorineural hearing loss * Bilateral severe-to-profound hearing loss that meets current cochlear implant criteria (\<50% open-set sentence recognition in quiet scores in the ear to be implanted and \<60% in the best-aided condition) * English spoken as the primary language. * Willingness to participate in and to comply with all requirements of the study * Subject may receive bilateral simultaneous cochlear implants.

Exclusion criteria

* Previous cochlear implant experience * Congenital hearing loss (for the purpose of this study, onset prior to 2 years-of-age). * Ossification, absence of cochlear development or any other cochlear anomaly that might prevent complete insertion of the electrode array. * Normal hearing in one or both ears. * Hearing loss of neural or central origin (e.g., deafness due to lesions on the acoustic nerve or central auditory pathway). * Active middle-ear infection. * Unwillingness and/or inability of the candidate to comply with all investigational requirements including, but not limited to, study protocol and surgical procedure.

Design outcomes

Primary

MeasureTime frameDescription
CNC Monosyllabic Word Performance - Treated Ear12 monthsCNC Word Test is a validated test of open-set word recognition. The test consists of 10 lists with 50 monosyllabic words in each list. Subject responses are scored for both words and phonemes correct in the correct sequence. Subjects will be tested using a configuration of speech at 0º azimuth in quiet.

Countries

United States

Participant flow

Participants by arm

ArmCount
Implanted
Subjects who met study inclusion and completed the primary endpoint.
38
Total38

Baseline characteristics

CharacteristicImplanted
Age at onset of hearing loss40.8 years
Age, Continuous63.6 years
Preoperative CNC word score - Treated ear5.6 percent correct
STANDARD_DEVIATION 1.4
Sex: Female, Male
Female
18 Participants
Sex: Female, Male
Male
20 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 38
serious
Total, serious adverse events
0 / 38

Outcome results

Primary

CNC Monosyllabic Word Performance - Treated Ear

CNC Word Test is a validated test of open-set word recognition. The test consists of 10 lists with 50 monosyllabic words in each list. Subject responses are scored for both words and phonemes correct in the correct sequence. Subjects will be tested using a configuration of speech at 0º azimuth in quiet.

Time frame: 12 months

ArmMeasureValue (MEAN)Dispersion
ImplantedCNC Monosyllabic Word Performance - Treated Ear56.8 percent correctStandard Error 3.9

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026